CLEC4C and lupus erythematosus: Despite the rarity of the pDC population, they have been implicated in multiple immune-mediated inflammatory disorders (IMIDs) (61) evidenced by an ongoing phase II clinical trial testing the efficacy of litifilimab, a monoclonal antibody against pDC-specific blood dendritic cell antigen 2 (BDCA2), in systemic (66) and cutaneous (67) lupus erythematosus to dampen type I IFN production (68, 69).